<DOC>
	<DOCNO>NCT00442702</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety Mircera darbepoetin alfa treatment anemia patient chronic kidney disease dialysis receive subcutaneous darbepoetin alfa maintenance therapy . Patients randomize either remain darbepoetin alfa therapy per local label , switch monthly subcutaneous Mircera , start dose 120 , 200 360 microgram , depend weekly dose darbepoetin alfa administer prior first dose Mircera . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera Patients With Chronic Kidney Disease , Not Dialysis .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic kidney disease , require dialysis ; receive darbepoetin alfa maintenance therapy &gt; =8 week screen , screening/baseline period . overt gastrointestinal bleeding within 8 week screen , screening/baseline period ; transfusion red blood cell within 8 week screen , screening/baseline period ; active malignant disease ; previous treatment Mircera .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>